Scarica l'app Stockscreener
8.81
0.34%
0.03
Pre-mercato:
8.87
0.06
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.78
Aprire:
$8.76
Volume 24 ore:
5.66M
Relative Volume:
2.40
Capitalizzazione di mercato:
$1.14B
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-14.21
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
+31.49%
1M Prestazione:
+70.74%
6M Prestazione:
-11.81%
1 anno Prestazione:
-46.67%
Intervallo 1D:
$8.55
$9.04
Intervallo di 1 settimana:
$6.65
$9.06
Portata 52W:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Confronta NEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.81 | 1.13B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
487.53 | 186.06B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.79 | 147.38B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
639.45 | 51.77B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
125.21 | 35.62B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
183.74 | 32.44B | 15.70B | 1.24B | 2.01B | 6.91 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
Ranking NeoGenomics Inc. among high performing stocks via toolsGap Down & Free Long-Term Investment Growth Plans - Newser
When is the best time to exit NeoGenomics Inc.July 2025 Analyst Calls & High Yield Equity Trading Tips - Newser
Is NeoGenomics Inc. meeting your algorithmic filter criteriaJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Is now a turning point for NeoGenomics Inc.2025 Support & Resistance & Fast Gain Swing Alerts - Newser
Chart based analysis of NeoGenomics Inc. trendsTrend Reversal & AI Forecast Swing Trade Picks - Newser
Does NeoGenomics Inc. have a sustainable dividendTrade Analysis Report & Risk Managed Investment Strategies - خودرو بانک
Applying sector rotation models to NeoGenomics Inc.July 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - Newser
What is NeoGenomics Inc. s debt to equity ratioJuly 2025 PostEarnings & High Win Rate Trade Tips - خودرو بانک
Is now a turning point for NeoGenomics IncIndex Update & Technical Pattern Based Buy Signals - Newser
What data driven models say about NeoGenomics Inc.’s futureJuly 2025 Chart Watch & Low Drawdown Investment Ideas - Newser
NeoGenomics reports Q2 revenue of $181.3mln, net loss of $45.1mln. - AInvest
Fort Myers cancer lab firm wins federal patent lawsuit - Business Observer
Neogenomics shares fall 1.25% premarket after court rules in favor of patent invalidity. - AInvest
Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics - MSN
Applying big data sentiment scoring on NeoGenomics Inc.Dollar Strength & Risk Managed Investment Strategies - Newser
Does NeoGenomics Inc. meet Warren Buffett’s criteriaTrade Risk Summary & Daily Oversold Stock Bounce Ideas - خودرو بانک
Will NeoGenomics Inc. outperform the market in YEARVolume Spike & Daily Chart Pattern Signals - خودرو بانک
Real time social sentiment graph for NeoGenomics Inc.July 2025 Levels & Risk Adjusted Swing Trade Ideas - Newser
Why is NeoGenomics Inc. stock going upCPI Data & Fast Entry Momentum Trade Alerts - خودرو بانک
Technical Charts Suggest Momentum Shift in CCRN getLinesFromResByArray error: size == 0 - kangso.co.kr
Full technical analysis of NeoGenomics Inc. stockJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
NeoGenomics rallies after court win in Natera patent dispute - MSN
Applying big data sentiment scoring on NeoGenomics IncWeekly Trade Recap & High Conviction Investment Ideas - Newser
Neogenomics Soars 21.64% on Legal Victory, Cancer Diagnostics Dominance - AInvest
Is a relief rally coming for NeoGenomics Inc. holdersJuly 2025 Outlook & Growth Oriented Trade Recommendations - Newser
How to interpret RSI for NeoGenomics Inc. stockMarket Volume Report & Free High Accuracy Swing Entry Alerts - Newser
What’s next for NeoGenomics Inc. stock priceEarnings Recap Summary & Short-Term High Return Strategies - Newser
Can NeoGenomics Inc. rally from current levels2025 Retail Activity & Daily Momentum Trading Reports - Newser
Using Python tools to backtest NeoGenomics Inc. strategiesLayoff News & Fast Momentum Entry Tips - Newser
Has NeoGenomics Inc. formed a bullish divergenceGap Down & Weekly Setup with High ROI Potential - Newser
Signal strength of NeoGenomics Inc. stock in tech scannersInsider Selling & Fast Gain Swing Alerts - Newser
Automated trading signals detected on NeoGenomics Inc.July 2025 Trends & Consistent Profit Trade Alerts - Newser
Analysts Backtest Strategies on NeoGenomics Inc. With Promising Results getLinesFromResByArray error: size == 0 - thegnnews.com
NeoGenomics Sees Price Target Reduced Amidst Steady Optimism - StocksToTrade
NeoGenomics Inc. stock outlook for YEARPortfolio Profit Report & Fast Gain Swing Alerts - Newser
Can swing trading help recover from NeoGenomics Inc. lossesTrade Exit Summary & Low Risk High Win Rate Picks - Newser
Does NeoGenomics Inc. qualify in momentum factor screeningJuly 2025 Market Mood & Safe Swing Trade Setups - Newser
Can NeoGenomics Inc. deliver alphaWeekly Stock Recap & Fast Gain Swing Trade Alerts - sundaytimes.kr
Can volume confirm reversal in NeoGenomics Inc.2025 Winners & Losers & Real-Time Volume Trigger Notifications - Newser
NeoGenomics Remains a Buy: Analyst Confirms Positive Sentiment and Consensus Price Target of $8.50. - AInvest
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):